Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial

Jann Storsaeter*, Hans Hallander, Conor P. Farrington, Patrick Olin, Roland Möllby, Elizbeth Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

87 Citations (Scopus)

Abstract

A placebo-controlled efficacy trial of two acellular pertussis vaccines carried out in Sweden in 1986-1987 used culture confirmation as the principal case definition. However, the sensitivity of pertussis culture is low, and secondary analyses using more sensitive serological diagnostic criteria have therefore been carried out. These analyses confirm that vaccination with pertussis toxoid alone does protect against typical whooping cough with laboratory confirmation, but show that it does not protect against infection or colonization. There is evidence that the addition of filamentous haemagglutinin provides some protection against infection. Bacterial isolation rates were lower in vaccinated than unvaccinated children with serologically confirmed pertussis and increased with disease severity.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalVaccine
Volume8
Issue number5
DOIs
Publication statusPublished - Oct 1990

Keywords

  • Pertussis
  • acellular vaccine
  • phase III trial

Fingerprint

Dive into the research topics of 'Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial'. Together they form a unique fingerprint.

Cite this